San Diego-based life sciences tool maker Illumina said Thursday that it has completed its acquisition of Verinata Health, which provides non-invasive tests for early identification of fetal chromosomal abnormalities. The deal--which had been announced originally in January--was worth $450M, including potential milestone payments. Illumina said the acquisition gives its access to Verinata's prenatal tests and intellectual property portfolio. Verinata had been venture backed by Alloy Ventures, Mohr Davidow Ventures, and Sutter Hill Ventures.
Top NewsFriday, February 22, 2013
Illumina Completes Verinata Health Buy